ReviewAntibiotics (Basel, Switzerland)2022
Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice.
Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Effectiveness and tolerability of low dose clindamycin for treatment of prosthetic joint infections, a retrospective cohort study.BMC infectious diseases · 2026Article
- Revolutionizing Antibiotic Delivery: Harnessing 3D-Printing Technology to Combat Bacterial Resistance.Current pharmaceutical design · 2026Review
- Feasibility of dried blood spot collection for caffeine pharmacokinetic studies in microgravity: Insights from parabolic flight campaigns.British journal of clinical pharmacology · 2026Article
- Insights into interspecies protein binding variability using clindamycin as an example.The Journal of antimicrobial chemotherapy · 2025Article
- A Complicated Microbiology Diagnosis and Treatment of Tonsillopharyngitis in Pregnancy: A Case Report.Case reports in medicine · 2025Article
- Antimicrobials in Orthopedic Infections: Overview of Clinical Perspective and Microbial Resistance.Medicina (Kaunas, Lithuania) · 2024Review
- Systemic antibiotic prophylaxis in arthroplasty - a narrative review of how many doses are optimal.EFORT open reviews · 2024Review
- Synthetic lincosamides iboxamycin and cresomycin are active against ocular multidrug-resistant methicillin-resistant Staphylococcus aureus carrying erm genes.Journal of global antimicrobial resistance · 2024Article
- Review
- Oral clindamycin for peritonitis due toJAC-antimicrobial resistance · 2024Article
- Increasing Rate of FatalMicroorganisms · 2024Article
- Targeted Clindamycin Delivery Systems: Promising Options for Preventing and Treating Bacterial Infections Using Biomaterials.International journal of molecular sciences · 2024Review
- Inducible clindamycin resistance among clinical Gram-positive cocci in a tertiary hospital in Niger Republic.Access microbiology · 2024Article
- Review
- Clindamycin-Loaded Nanosized Calcium Phosphates Powders as a Carrier of Active Substances.Nanomaterials (Basel, Switzerland) · 2023Article
- Developmental Pharmacokinetics of Antibiotics Used in Neonatal ICU: Focus on Preterm Infants.Biomedicines · 2023Review
- Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review-Part II.Antibiotics (Basel, Switzerland) · 2022Review
- Editorial for the Special Issue: "Therapeutic Drug Monitoring of Antimicrobials".Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the increase in bacterial resistance and the decrease in the development of new antibiotics, the appropriate use of old antimicrobials has become even more compulsory. Clindamycin is a lincosamide antibiotic approved for adults and children as a drug of choice for systemic treatment of staphylococcal, streptococcal, and gram-positive anaerobic bacterial infections. Because of its profile and high bioavailability, it is commonly used as part of an oral multimodal alternative for prolonged parenteral antibiotic regimens, e.g., to treat bone and joint or prosthesis-related infections. Clindamycin is also frequently used for (surgical) prophylaxis in the event of beta-lactam allergy. Special populations (pediatrics, pregnant women) have altered cytochrome P450 (CYP)3A4 activity. As clindamycin is metabolized by the CYP3A4/5 enzymes to bioactive N-demethyl and sulfoxide metabolites, knowledge of the potential relevance of the drug's metabolites and disposition in special populations is of interest. Furthermore, drug-drug interactions derived from CYP3A4 inducers and inhibitors, and the data on the impact of the disease state on the CYP system, are still limited. This narrative review provides a detailed survey of the currently available literature on pharmacology and pharmacokinetics and identifies knowledge gaps (special patient population, drug-drug, and drug-disease interactions) to describe a research strategy for precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.